4HAYAKAWA H,FUJIMAKI K,SHIMIZU Y,et al.Metabolic fate of pazufloxacin mesilate in human and animals[J].Jpn J Chemother,1999,47(suppl 1):S81-S85.
5YANGXY YOUXP.Pharmacological study and clinical application of injectable pazadloxncin mesilate[J].国外医药：抗生素分册,2003,24(2):80-88.
6LIUL LIKX LIY etal.High performance liquid chromatography for the determination of pazufloxacin mesylate in human serum[J].药物分析杂志,2004,24(5):529-531.
7ARAKI H,OGAKE N,TSUNEDA R,et al.Muscle distribution of antimicrobial agents after a single intravenous administration to rats[J].Drug Metab Pharmacokinet,2002,17(3):237-244.
8Kobayashl H. Interim results from a multieentre clinical trial of T-3761 in Japan [J]. Drug,1995,49(Suppl 2):470
9Shimada K. Optimal clinical dose of pazufloxacin mesilate in respiratory tract infection or complicated urinary tract infection [J]. 日本化学疗法学会杂志，2002，50(7)：435
10Muratani T, Inoue M, Mitsuhashi S, In vitro of T-3761 ,a new fluoroquinolone [J]. Antitnicrob Agent Chemother,1992,36(10):2293
